331 results
Page 2 of 17
8-K
EX-99.1
md6hmsh3ya3tvz8
14 Nov 22
ImmunoGen Announces FDA Accelerated Approval of ELAHEREā¢ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
5:23pm
8-K
EX-99.1
wufw7q86ic 2i5
4 Nov 22
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
6:41am
8-K
EX-99.1
e7l2mprp6 4t
1 Nov 22
ImmunoGen Announces Departure of Chief Commercial Officer
9:09am
8-K
EX-99.1
8pbb2 3y7gt
31 Aug 22
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
6:40am
8-K
EX-99.1
l3570v55qs6t6c4jy9j
29 Jul 22
ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results
6:41am
8-K
EX-99.1
xbllboe0
6 May 22
ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
6:41am
8-K
EX-99.1
0vry2qditmafwhdh hr2
25 Feb 22
ImmunoGen Reports Recent Progress and 2021 Financial Results
6:47am
8-K
EX-99.1
klrdk9bkwv2
16 Feb 22
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
4:53pm
8-K
EX-1.1
l4t7xzjob n9n
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-99.3
dn3g9am
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
424B5
x5m57ebhc4ah
3 Dec 21
Prospectus supplement for primary offering
4:06pm
424B5
4kq75p
30 Nov 21
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.1
dbi qeps7
29 Oct 21
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
6:43am
424B5
v96lmlnbolxs
12 Aug 21
Prospectus supplement for primary offering
10:11am